International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels: International Diabetes Federation; 2019.
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes: 2020. Diabetes Care 2020;43(Suppl. 1):S98–S110. DOI: 10.2337/dc20-S009.
Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide (GLP-1) analogue semaglutide. J Med Chem 2015;58(18). DOI: 10.1021/acs.jmedchem.5b00726.
Buckley ST, Baekdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018;10(467):eaar7047. DOI: 10.1126/scitranslmed.aar7047.
Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 2017;318(15):1460–1470. DOI: 10.1001/jama.2017.14752.
Ismail R, Csoka I. Novel strategies in the oral delivery of antidiabetic peptide drugs: insulin, GLP 1 and its analogs. Eur J PharmBiopharm 2017;115:257–267. DOI: 10.1016/j.ejpb.2017.03.015.
